 |
 |
||
| MSH News | |
||
 |
Events | ||
| Technical Seminars | |||
| Stories
|
|||
| Annual Report | |||
|
|||
 |
|||
| Download MSH Annual Report in PDF format or order a hardcopy from the eBookstore | |||
|
|
|
|
 |
 |
Home: News Room: Events: World Conference on Lung Health—2005 MSH Presents at the 36th World Conference on Lung Health October 18-23, 2005 Workshops
Symposium
Poster Sessions
Wednesday, October 19, 2005, 9:00-17:00 Sponsors:
DESCRIPTION: Strong pharmaceutical management is one of the key pillars of effective tuberculosis (TB) control: without appropriate selection, effective procurement, distribution, stock management and rational use of TB medicines and related supplies, patients will not be cured of the disease and countries will not reach global targets. Interventions to strengthen TB pharmaceutical management are most effective if guided by informed decision-making. This session seeks to introduce specific guidelines to effectively improve the current situation in TB drug supply and to share with participants examples of practical solutions currently applied by some National TB Programmes (NTPs) that can be used to strengthen their supply systems. Part II of the workshop gives participants hands-on experience with tools used by Stop TB’s Global TB Drug Facility (GDF) in providing quality TB medicines to national TB programs and in identifying needs for technical assistance in pharmaceutical management. OBJECTIVES:
SPEAKERS:
Sunday, October 23, 2005 - 9:00-17:00 DESCRIPTION: This invitation-only workshop is the third on incentives and enablers (I&E) to improve TB control. Previous workshops were sponsored in partnership with Stop TB. In 2001, a team from Stop TB/WHO/World Bank and RPM Plus/MSH stimulated broad discussion of the available I&E evidence base, and in 2003, the focus was methods and challenges in evaluating the impact of I&E on TB program performance. Since then, a number of new I&E schemes have been initiated, many of them funded through GFATM and Fidelis proposals on a pilot basis. It is clear that the role of I&E in TB control is growing, and evaluating the experiences and evidence is critical at this stage. This year the focus is assessing the impact evidence and the implementation experiences with I&E, in the context of scaling up their use in TB control, and particuarly with regard to the role that I&E could play in supporting scale-up of key DOTS expansion strategies such PPM and CB-DOTS. The key instruments will be review of a draft document, "Evaluating TB I&E in the context of scale-up: evidence and experiences", and working groups to discuss scale-up issues. The report will be finalized based on workshop input. SECTION: Tuberculosis COORDINATOR: Sangeeta Mookherji and Alix Beith
Thursday, October 20, 2005 – 14:00-16:15 DESCRIPTION: Many tuberculosis programmes have used incentives and enablers (I&E) to improve case detection and treatment adherence, without assessing their impact and cost-effectiveness through well-designed evaluations, particularly in relation to other interventions to improve DOTS programme performance. However, there have recently been a number of efforts to strengthen I&E evaluation in TB control. Further, new strategies to expand DOTS emphasise engaging new care providers and communities, and I&E are proving to be important in both areas. This symposium will share recent evaluation results, highlight common challenges in I&E implementation and evaluation, and suggest how I&E might be part of context-specific strategies to expand DOTS. Round table discussion will focus on policy and scale up recommendations. OBJECTIVES:
COORDINATOR: Sangeeta Mookherji PRESENTATIONS:
|
||
